Home DNA Damage/DNA Repair Antineoplastic and Immunosuppressive Antibiotics activator - DNA/RNA Synthesis inhibitor - Autophagy activator Actinomycin D (Dactinomycin) For research use only.

Actinomycin D (Dactinomycin)

Synonyms: Act D, RASP-101

Actinomycin D (Dactinomycin, Act D, RASP-101) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. Actinomycin D is an autophagy activator, induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.

Actinomycin D (Dactinomycin) Chemical Structure

Actinomycin D (Dactinomycin) Chemical Structure

CAS: 50-76-0

Selleck's Actinomycin D (Dactinomycin) has been cited by 71 publications

Purity & Quality Control

Batch: Purity: 99.74%
99.74

Related compound libraries

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780 Cytotoxicity assay Cytotoxicity against human A2780 cells, Activity = 0.0017 μM. 16562838
A549 Cytotoxicity assay 48 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000201 μM. 27736087
PC3 Cytotoxicity assay 48 hrs Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000276 μM. 27736087
L1210 Function assay 3 hrs Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.009 μM. 330857
L1210 Function assay 3 hrs Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.4 μM. 330857
L1210 Function assay Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay, ED50 = 0.015 μM. 573799
L1210 Function assay Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay, ED50 = 0.6 μM. 573799
P388 Function assay Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro), ED50 = 0.046 μM. 6169834
P388 Function assay Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro), ED50 = 0.996 μM. 6169834
HMO2 Cytotoxicity assay 48 hrs Cytotoxicity against human HMO2 cells after 48 hrs by sulforhodamine assay, GI50 = 0.3 μM. 10757717
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay, GI50 = 0.5 μM. 10757717
HepG2 Cytotoxicity assay 48 hrs Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay, GI50 = 1 μM. 10757717
B104-1-1 Growth inhibitory assay Growth inhibitory activity was tested against B104-1-1 cells, GI50 = 0.0007 μM. 10888331
Hep G2 Cytotoxicity assay Cytotoxicity against human Hep G2 cells, GI50 = 0.0012 μM. 16933866
HM02 Cytotoxicity assay Cytotoxicity against human HM02 cells, GI50 = 0.0016 μM. 16933866
P388 Antiproliferative assay 48 hrs Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.0002 μM. 2778449
HT-29 Antiproliferative assay 96 hrs Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.223 μM. 2778449
L1210 Function assay Inhibition of synthesis of [5-3H]-uridine into RNA in L1210 cells., IC50 = 0.019 μM. 3397991
L1210 Function assay Inhibition of synthesis of [methyl-14C] thymidine into DNA, in L1210 cells., IC50 = 0.38 μM. 3397991
Jurkat T Function assay Inhibitory concentration against Human Jurkat T cells, IC50 = 0.0045 μM. 10212121
B104-1-1 Function assay In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined, IC50 = 5 μM. 10888331
Jurkat T Function assay 48 hrs Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.0045 μM. 11052798
C8166 Antitumor assay Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells, IC50 = 0.0008 μM. 12431048
CCRF-CEM Antitumor assay Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells, IC50 = 0.001 μM. 12431048
CD4+T Antitumor assay Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells, IC50 = 0.001 μM. 12431048
MOLT-4 Antitumor assay Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells, IC50 = 0.001 μM. 12431048
G-361 Antitumor assay Antitumor activity against human skin melanoma G-361 cells, IC50 = 0.001 μM. 12431048
MT-4 Antitumor assay Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells, IC50 = 0.001 μM. 12431048
CCRF-SB Antitumor assay Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells, IC50 = 0.002 μM. 12431048
SKMEK-28 Antitumor assay Antitumor activity against human skin melanoma SKMEK-28 cells, IC50 = 0.002 μM. 12431048
Raji Antitumor assay Antitumor activity against human Burkitt lym phoma Raji cells, IC50 = 0.002 μM. 12431048
5637 Antitumor assay Antitumor activity against human bladder carcinoma 5637 cells, IC50 = 0.003 μM. 12431048
Wil2-NS Antitumor assay Anti tumor activity against human splenic B-lympho blastoid Wil2-NS cells, IC50 = 0.003 μM. 12431048
Hep-2 Antitumor assay Antitumor activity against larynx carcinoma Hep-2 cells, IC50 = 0.004 μM. 12431048
SK-MES-1 Antitumor assay Antitumor activity against human lung squamous carcinoma SK-MES-1 cells, IC50 = 0.004 μM. 12431048
ACHN Antitumor assay Antitumor activity against human renal adenocarcinoma ACHN cells, IC50 = 0.005 μM. 12431048
KB Function assay Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%, IC50 = 0.005 μM. 12431048
HT-29 Antitumor assay Antitumor activity against human colon adenocarcinoma HT-29 cells, IC50 = 0.006 μM. 12431048
MCF-7 Antitumor assay Antitumor activity against human breast adenocarcinoma MCF-7 cells, IC50 = 0.006 μM. 12431048
CRL7065 Antitumor assay Antitumor activity against human foreskin fibroblasts CRL7065 cells, IC50 = 0.007 μM. 12431048
DU145 Antitumor assay Antitumor activity against human prostate carcinoma DU145 cells, IC50 = 0.008 μM. 12431048
Hela Antitumor assay Antitumor activity against cervix carcinoma Hela cells cells, IC50 = 0.008 μM. 12431048
HepG2 Antitumor assay Antitumor activity against human hepatocellular carcinoma HepG2 cells, IC50 = 0.01 μM. 12431048
C8166 Antitumor assay Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells., IC50 = 0.00008 μM. 12431049
MT-4 Antitumor assay Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells., IC50 = 0.0009 μM. 12431049
G361 Antitumor assay Antitumor activity against human skin melanoma G361 cells., IC50 = 0.001 μM. 12431049
MOLT-4 Antitumor assay Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells., IC50 = 0.001 μM. 12431049
CCRF-SB Antitumor assay Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells., IC50 = 0.001 μM. 12431049
Raji Antitumor assay Antitumor activity against human Burkitt lymphoma Raji cells., IC50 = 0.002 μM. 12431049
5637 Antitumor assay Antitumor activity against human bladder carcinoma 5637 cells., IC50 = 0.003 μM. 12431049
CCRF-CEM Antitumor assay Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells., IC50 = 0.003 μM. 12431049
Wil-NS Antitumor assay Antitumor activity against human splenic B-lymphoblastoid Wil-NS cells., IC50 = 0.003 μM. 12431049
Hep-2 Antitumor assay Antitumor activity against Hep-2 larynx carcinoma cells., IC50 = 0.004 μM. 12431049
ACHN Antitumor assay Antitumor activity against human renal adenocarcinoma ACHN cells., IC50 = 0.005 μM. 12431049
MCF-7 Antitumor assay Antitumor activity against human breast adenocarcinoma MCF-7 cells., IC50 = 0.006 μM. 12431049
HT-29 Antitumor assay Antitumor activity against human colon adenocarcinoma HT-29 cells., IC50 = 0.006 μM. 12431049
HepG-2 Antitumor assay Antitumor activity against human hepatocellular carcinoma HepG-2 cells., IC50 = 0.01 μM. 12431049
HeLa Antitumor assay Antitumor activity against HeLa cervical carcinoma cells., IC50 = 0.04 μM. 12431049
CCRF-CEM Cytotoxicity assay Cytotoxicity in human leukemic CCRF-CEM cells., IC50 = 1.6 μM. 14667232
A2780 Cytotoxicity assay Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. 15844934
A2780 Cytotoxicity assay Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. 16180816
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. 16309323
Vero Cytotoxicity assay 48 hrs Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. 16309323
Hep2 Cytotoxicity assay 48 hrs Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay, IC50 = 0.006 μM. 16309323
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.011 μM. 16309323
Vero Cytotoxicity assay 48 hrs Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.071 μM. 16309323
Hep2 Cytotoxicity assay 48 hrs Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.191 μM. 16309323
MOLT3 Cytotoxicity assay Cytotoxicity against MOLT3 Leukemia cells by MTS assay, IC50 = 1 μM. 16420056
U937 Cytotoxicity assay Cytotoxicity against U937 Lymphoma cells by MTS assay, IC50 = 1 μM. 16420056
Vero Cytotoxicity assay Cytotoxicity against normal vero kidney cells by MTS assay, IC50 = 11 μM. 16420056
Wil2-NS Antiproliferative assay Antiproliferative activity against human Wil2-NS cells by MTT assay, IC50 = 0.003 μM. 16913700
HeLa Antiproliferative assay Antiproliferative activity against human HeLa cells by MTT assay, IC50 = 0.04 μM. 16913700
CCRF-CEM Cytotoxicity assay 72 hrs Cytotoxicity against human CCRF-CEM cells after 72 hrs, IC50 = 0.0016 μM. 18329887
HeLa Antiproliferative assay 48 hrs Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.0004 μM. 18461997
HT29 Antiproliferative assay 48 hrs Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay, IC50 = 0.0029 μM. 18461997
U2OS Antiproliferative assay 48 hrs Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay, IC50 = 0.0032 μM. 18461997
HeLa Function assay 2 hrs Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 0.2624 μM. 20118940
HeLa Function assay 2 hrs Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5197 μM. 20118940
NCI-H460 Cytotoxicity assay 72 hrs Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay, IC50 = 0.008 μM. 20704331
SF268 Cytotoxicity assay 72 hrs Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay, IC50 = 0.016 μM. 20704331
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay, IC50 = 0.103 μM. 20704331
Vero Cytotoxicity assay 20 hrs Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay, IC50 = 11 μM. 21093966
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0011 μM. 22705001
A549 Cytotoxicity assay 48 hrs Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0072 μM. 22705001
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.024 μM. 22705001
Vero Cytotoxicity assay 48 hrs Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.071 μM. 22705001
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs, IC50 = 0.0011 μM. 24709561
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs, IC50 = 0.0016 μM. 24709561
Hep2 Cytotoxicity assay 48 hrs Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs, IC50 = 0.0062 μM. 24709561
Vero Cytotoxicity assay 48 hrs Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs, IC50 = 0.01 μM. 24709561
Vero Cytotoxicity assay 48 hrs Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs, IC50 = 0.072 μM. 24709561
Hep2 Cytotoxicity assay 48 hrs Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs, IC50 = 0.17 μM. 24709561
HEK293 Function assay 30 mins Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method, IC50 = 9 μM. 25569119
HeLa Cytotoxicity assay 48 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0011 μM. 28923386
A549 Cytotoxicity assay 48 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0072 μM. 28923386
Vero Cytotoxicity assay 48 hrs Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.011 μM. 28923386
MCF7 Cytotoxicity assay 48 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.024 μM. 28923386
Vero Cytotoxicity assay 48 hrs Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.071 μM. 28923386
B16 Growth inhibition assay In vitro 50% Growth inhibition of sensitive B16 cells., ID50 = 0.003 μM. 3397991
L1210 Growth inhibition assay 50% Inhibition of growth of L1210 cells in culture., ID50 = 0.0601 μM. 3397991
P388/ADR Growth inhibition assay In vitro 50% Growth inhibition of actinomycin resistant P388/ADR cells, ID50 = 2.5 μM. 3397991
HeLa Apoptosis assay Induction of apoptosis in human HeLa cells assessed as DNA fragmentation by agarose gel electrophoresis 22705001
NCI-H157 Apoptosis assay 10 uM 5 hrs Induction of apoptosis in human NCI-H157 cells assessed as live cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry 22863528
HeLa Cytotoxicity assay 1 uM 18 hrs Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 1 uM after 18 hrs by inverse MTT assay 25028062
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
Daoy qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Actinomycin D (Dactinomycin, Act D, RASP-101) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. Actinomycin D is an autophagy activator, induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
Targets
autophagy [3] cell cycle [1]
(Cell-based assay)		 DNA repair [2]
(Cell-free assay)
0.4 nM 0.42 μM
In vitro
In vitro

Actinomycin D markedly reduces the SMC proliferation via the inhibition of BrdU incorporation at 80 nM. This is further supported by the G1-phase arrest using a flowcytometric analysis. The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf are all suppressed by actinomycin D. Extracellular signalregulated kinases (Erk) involved in cell-cycle arrest are found to be increased by actinomycin D.[1]
Cell Research Cell lines A10 cells (Vascular SMC)
Concentrations 80 nM, 800 nM, 8 μM
Incubation Time 18-24 h
Method

Cultured SMC are starved for 24 h followed by incubation with various doses of actinomycin D at 37℃. Drug treatment is carried out for 18-24 h. Since actinomycin D is dissolved in 0.1% DMSO, a vehicle control containing DMSO is also included.
Experimental Result Images Methods Biomarkers Images PMID
Western blot PAR AIF / Histone H3 / GAPDH NAT10 / p53 / Ac-p53-K120 / Mdm2 / p21 / β-actin L23 / p53 / MDM2 / p21 / Tubulin L11 / L23 / p53 / MDM2 / p21 / Tubulin 33168626
Growth inhibition assay Cell viability Cell Number Cell viability 33168626
SYTOX Green plate reader assay DNA release 29736268
Immunofluorescence PAR PAR Tom20 / AIF NAT10 / p53 GFP-NAT10 DNA 33168626
In Vivo
In vivo

Actinomycin D targets survival proteins TOSO, BCL2 and MCL1 and is active in two different mouse models that are characterized by either unmutated B-cell receptor or inactive p53 function, both of which are known negative prognostic factors in CLL.[3]
Animal Research Animal Models C57BL/6 wild-type mice engrafted with tumor cells from Em-TCL-1 transgenic mice
Dosages 0.06 mg/kg
Administration IP
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05858723 Not yet recruiting Allergic Contact Dermatitis National Allergy Research Center Denmark August 2023 Not Applicable
NCT05952154 Recruiting Nonobstructive Hypertrophic Cardiomyopathy Xiang Wei|Tongji Hospital July 2023 Not Applicable
NCT05957419 Recruiting Hypertrophic Obstructive Cardiomyopathy Xiang Wei|Guangdong Provincial People''s Hospital|Beijing Anzhen Hospital|Fudan University|Second Hospital of Jilin University|Tongji Hospital July 2023 Not Applicable

Chemical lnformation & Solubility

Molecular Weight 1255.42 Formula

C62H86N12O16
CAS No. 50-76-0 SDF --
Storage (From the date of receipt) 3 years -20°C(in the dark) powder

In vitro
Batch:

DMSO : 100 mg/mL ( (79.65 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) supplier | purchase Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) cost | Actinomycin D (Dactinomycin) manufacturer | order Actinomycin D (Dactinomycin) | Actinomycin D (Dactinomycin) distributor